StoneX Maintains Buy on NeoGenomics, Raises Price Target to $20
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
StoneX analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $16 to $20.
StoneX analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $16 to $20.